Anti-PHF-tau antibodies and uses thereof
AssigneeJanssen Biotech, Inc.
InventorsMarc Mercken, Thomas Malia, Marianne Borgers, Kristof Van Kolen
Life of this patent
Estimating the term…
Abstract
Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.
Claims40
An isolated antibody or antigen binding fragment thereof which binds to PHF tau comprising:
- a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:7,
- b) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:8,
- c) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:9,
- d) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:19,
- e) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:20, and
- f) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:21.
An isolated antibody or antigen binding fragment thereof which binds to PHF tau comprising:
- a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:80,
- b) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:81,
- c) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:9,
- d) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:70,
- e) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:20, and
- f) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:21.
An isolated antibody or antigen binding fragment thereof which binds to PHF tau comprising:
- a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:71,
- b) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:72,
- c) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:73,
- d) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:70,
- e) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:20, and
- f) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:21.
An isolated monoclonal antibody or antigen-binding fragment thereof comprising a heavy chain variable region having the polypeptide sequence of amino acids 1-188 of SEQ ID NO:74, and a light chain variable region having the polypeptide sequence of amino acids 1-107 of SEQ ID NO:75.
An isolated monoclonal antibody or antigen-binding fragment thereof comprising a heavy chain variable region having the polypeptide sequence of amino acids 1-118 of SEQ ID NO:76, and a light chain variable region having the polypeptide sequence of amino acids 1-107 of SEQ ID NO:77.
An isolated monoclonal antibody or antigen-binding fragment thereof comprising a heavy chain variable region having the polypeptide sequence of SEQ ID NO:27, and a light chain variable region having the polypeptide sequence of SEQ ID NO:31.
Dependencies are inferred from the claim text.